Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Abbvie inc. crawled time : 14:15 save search
Breast Implants Market size worth $ 2.02 Billion, Globally, by 2028 at 5.22% CAGR: Verified Market Research®
Published: 2021-11-11 (Crawled : 14:15) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
implant research market
AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis
Published: 2021-11-09 (Crawled : 14:15) - biospace.com/
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
rheumatoid arthritis response
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
Published: 2021-09-09 (Crawled : 14:15) - biospace.com/
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.83%
H: 0.27%
C: -1.98%
GMAB | $28.67 1.2% 41K
|
Health Technology
|
| O: -1.2%
H: 0.95%
C: -0.77%
trial t-cell lancet
A $138.8 Billion Global Opportunity for Nanotechnology in Drug Delivery by 2026 - New Research from StrategyR
Published: 2021-09-03 (Crawled : 14:15) - prnewswire.com
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.75%
H: 0.8%
C: 0.4%
drug technology research drug delivery liver
AbbVie to Host Second-Quarter 2021 Earnings Conference Call
Published: 2021-07-07 (Crawled : 14:15) - biospace.com/
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: 0.16%
H: 0.91%
C: 0.72%
conference
Global Facial Aesthetics Market to Witness $ 1.45 Billion growth during 2021-2025 | Technavio
Published: 2021-06-14 (Crawled : 14:15) - prnewswire.com
BHC | $8.655 0.64% 750K
|
Health Technology
|
| O: 0.06%
H: 0.75%
C: -0.97%
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.3%
H: 0.36%
C: 0.29%
ANIK | News | $25.66 0.9% 7.5K
|
Health Technology
|
| O: -0.3%
H: 1.3%
C: -2.01%
aesthetic growth
X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract
Published: 2021-05-12 (Crawled : 14:15) - globenewswire.com
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.03%
H: 1.0%
C: 0.1%
XFOR | $1.2 530K
|
Health Technology
|
| O: -1.39%
H: 18.59%
C: 3.08%
ongoing phase 1 positive trial phase 1b phase 2b
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.